Luzhu Pharmaceutical: Recombinant Human Follicle-Stimulating Hormone Injection Receives Drug Registration Certificate

Lijzhu Pharmaceutical Announcement: The holding subsidiary Lijzhu Monoclonal Antibody has received the Drug Registration Certificate for the recombinant human follicle-stimulating hormone injection, approved and issued by the National Medical Products Administration. This drug is independently developed by Lijzhu Monoclonal Antibody. Indications include women with anovulation, women undergoing ovulation induction in assisted reproductive technology, and patients with severe deficiency of luteinizing hormone and follicle-stimulating hormone. The product is produced using recombinant gene technology. It is administered via an injection pen and has completed clinical evaluation for biosimilar drugs from Phase I to Phase III, and is equivalent to the original research drug. Cumulative R&D expenditure is approximately 122 million yuan.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned